Virus Destroying Or Inhibiting Patents (Class 514/3.7)
-
Publication number: 20130202646Abstract: In alternative embodiments, the invention provides cell-permeable recombinant or synthetic proteins to modulate autophagy, including a Tat-Atg5K130R (inhibitor of autophagy) and a Tat-Beclin 1 (stimulant or activator of autophagy), and nucleic acids expressing them and methods for making and using them, e.g., to treat conditions and disorders responsive to autophagy modulation (e.g., where autophagy is dysregulated), including neurodegeneration, cystic fibrosis, cancer, heart failure, diabetes, obesity, sarcopenia, aging, ischemia/reperfusion, inflammatory disorders including Crohns, ulcerative colitis, biliary cirrhosis, lysosomal storage diseases, infectious diseases associated with intracellular pathogens including viruses, bacteria, and parasites such as Trypanosomes and malaria.Type: ApplicationFiled: February 25, 2011Publication date: August 8, 2013Applicant: SAN DIEGO STATE UNIVERSITY (SDSU) FOUNDATIONInventor: Roberta A Gottlieb
-
Publication number: 20130202598Abstract: The present invention relates to activatable toxin complexes which include a cleavable inhibitory peptide. More specifically, the complexes comprise a cell targeting domain, a toxin catalytic domain, a specific protease cleavage site and an inhibitory peptide domain. The inhibitory peptide prevents the catalytic domain from exerting toxic effects until its release from the complex by the action of a protease, such a viral protease, at the protease cleavage site. Further provided are pharmaceutical compositions comprising the complexes and use thereof for treating infections and malignant disease.Type: ApplicationFiled: August 22, 2011Publication date: August 8, 2013Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Itai Benhar, Assaf Shapira, Meital Gal-Tanamy, Dana Greenfeld, Limor Nahary, Romy Zemel, Ran Tur-Kaspa
-
Publication number: 20130195884Abstract: The present invention relates to an agent for use as a modulator of apoptosis-factor-associated cell death, apoptosis, cell survival, migration and/or proliferation, a method of diagnosing or monitoring apoptosis-factor-associated conditions or disorders as well as a method of identifying a modulator of apoptosis-factor-associated cell death, apoptosis, cell survival, migration and/or proliferation. Preferably, the invention relates to TRAIL-induced cell death and/or TRAIL-induced apoptosis. Preferably the agents are used to stimulate and/or enable TRAIL-induced cell death or to inhibit TRAIL-induced cell death. The preferable use of the diagnostic tools is to diagnose sensitivity or resistance to TRAIL-induced cell death or induction of sensitivity or resistance to TRAIL-induced cell death by an agent.Type: ApplicationFiled: December 30, 2010Publication date: August 1, 2013Applicant: Deutsches KrebsforschungszentrumInventors: Michael Boutros, Henning Walczak, Sandra Steinbrink, Christina Falschlehner
-
Publication number: 20130196903Abstract: The present invention relates to novel multimeric inhibitors of viral entry into cells and their use for the prophylaxis and treatment of viral infections.Type: ApplicationFiled: August 11, 2011Publication date: August 1, 2013Applicant: JV BIO SRLInventor: Antonello Pessi
-
Publication number: 20130196902Abstract: This application describes compounds acting as, for example, ?-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases.Type: ApplicationFiled: January 31, 2013Publication date: August 1, 2013Applicant: Trevena, Inc.Inventors: Dennis Yamashita, Xiao Tao Chen
-
Publication number: 20130189225Abstract: Methods for increasing the efficiency of target tissue penetration of an adeno-associated virus (AAV) vector in a patient are provided. In some aspects, the methods involve inhibiting the interaction of the serum protein galectin 3 binding protein (G3BP) with AAV vector. Further provided are methods for reducing tissue distribution of a virus or for neutralizing a virus harbored by an organ destined for transplant, or newly transplanted, by administering a composition comprising G3BP.Type: ApplicationFiled: March 22, 2011Publication date: July 25, 2013Applicants: ASSOCIATION INSTITUT DE MYOLOGIE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, GENETHONInventors: Thomas Voit, Luis Garcia, Jérôme Denard, Fedor Svinartchouk
-
Publication number: 20130190228Abstract: The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.Type: ApplicationFiled: January 24, 2012Publication date: July 25, 2013Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Stacey L. Schultz-Cherry, Curtis R. Brandt, Jeremy C. Jones
-
Publication number: 20130189275Abstract: The present invention relates to a method of interfering with dengue infection comprising interfering with dengue virus binding to a syndecan present on a cell targeted by dengue virus. The present invention further relates to treating a patient for dengue virus infection comprising administering to a patient, either having a dengue infection or a patient exposed to dengue infection, an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus. The present invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier, and an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus.Type: ApplicationFiled: June 3, 2011Publication date: July 25, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Maria T. Arevalo, Patricia J. Simpson-Haidaris, Xia Jin, Huiyan Chen, Matthew H. Quinn
-
Publication number: 20130189363Abstract: ?-Hairpin peptidomimetics of the general formula Cyclo (-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-), enantiomers and pharmaceutically acceptable salts thereof, with Xaa1-Xaa14 being amino acid residues of certain types which are defined in the description and the claims, have anti-infective activity, e.g. to selectively inhibit the growth of or to kill microorganisms such as Bacillus subtilis and/or Shigella boydii. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: August 5, 2010Publication date: July 25, 2013Applicants: UNIVERSITÄT ZÜRICH, POLYPHOR AGInventors: Daniel Obrecht, Frank Otto Gombert, John Anthony Robinson, Krystyna Patora-Komisarska
-
Publication number: 20130183267Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.Type: ApplicationFiled: January 4, 2013Publication date: July 18, 2013Applicant: Enanta Pharmaceuticals, Inc.Inventor: Enanta Pharmaceuticals, Inc.
-
Publication number: 20130183289Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: September 13, 2008Publication date: July 18, 2013Applicant: Biogen Idec MA IncInventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Patent number: 8486382Abstract: Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus. IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.Type: GrantFiled: August 7, 2009Date of Patent: July 16, 2013Assignee: ZymoGenetics, Inc.Inventors: Yasmin A. Chandrasekher, Patricia A. McKernan
-
Publication number: 20130177528Abstract: Provided herein are compositions and methods for inhibiting viral infection of a host cell. The methods comprise contacting the the host cell with an effective amount of one or more polypeptides having a disintegrin domain. The polypeptide can be CN, VCN or modified ADAM-derived polypeptide (MAP), or a fusion protein comprising a CN, VCN or MAP.Type: ApplicationFiled: November 12, 2012Publication date: July 11, 2013Applicants: WESTERN UNIVERSITY OF HEALTH SCIENCES, UNIVERSITY OF SOUTHERN CALIFORNIAInventors: University of Southern California, Western University of Health Sciences
-
Patent number: 8481255Abstract: A scytovirin domain 1 (SD1) polypeptide, a nucleic acid encoding the polypeptide, and related fusion proteins, conjugates, isolated cells, vectors, and antibodies, as well as a method of inhibiting a viral infection using the same.Type: GrantFiled: September 30, 2011Date of Patent: July 9, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Barry R. O'Keefe, Chang-yun Xiong, James B. McMahon, Andrew Byrd
-
Publication number: 20130172238Abstract: Method for producing a modified oligonucleotide, wherein at least one polymer, preferably polyalkylene oxide, and/or a compound is covalently bound to the 5?-end or the 3?-end of the oligonucleotide via native ligation forming a native ligation site, with the proviso that the polymer and/or the compound is not a protein or peptide, if only the 5?-end of the oligonucleotide is modified by binding of the polymer or compound via native ligation. The invention is further directed to a modified oligonucleotide obtainable by the inventive method as well as the use of such modified oligonucleotide for the preparation of a medicament for preventing and/or treating a tumor, formation of metastasis, an immune disease or disorder, a cardiovascular disease or disorder, and/or a viral disease or disorder.Type: ApplicationFiled: June 10, 2011Publication date: July 4, 2013Inventors: Andreas Mitsch, Karl-Hermann Schlingensiepen, Bernd Betzler, Frank Jaschinski, Anneliese Schneider
-
Publication number: 20130171103Abstract: Compounds that selectively inhibit viral replication or the production of viral RNA or DNA, viral protein or virus induced cytopathic effects and compositions comprising such Compounds are described. Also described are methods of inhibiting viral replication or the production of viral RNA or DNA, viral protein or virus induced cytopathic effects using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.Type: ApplicationFiled: May 26, 2011Publication date: July 4, 2013Applicant: PTC Therapeutics, Inc.Inventors: Thomas Davis, Jason D. Graci, Zhengxian Gu, Christopher Trotta
-
Patent number: 8476225Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: December 1, 2010Date of Patent: July 2, 2013Assignee: Gilead Sciences, Inc.Inventors: Anthony Casarez, Mingzhe Ji, Choung U. Kim, Xiaoning C. Sheng, Qiaoyin Wu
-
Patent number: 8470771Abstract: The invention relates to a process for inhibiting the infection of influenza viruses and a polypeptide or protein medicine used therein. More particularly, the invention involves a process for inhibiting the highly pathogenic avian influenza virus (such as H5N1 subtype) infection and human influenza virus (such as H1N1 subtype and H3N2 subtype) infection, as well as the polypeptide or protein involved therein, and a polynucleotide encoding the polypeptide or protein and a vector or host cell expressing said polypeptide or protein.Type: GrantFiled: December 18, 2007Date of Patent: June 25, 2013Assignee: Institute of Microbiology, Chinese Academy of SciencesInventors: George Fu Gao, June Liu, Po Tien
-
Publication number: 20130156697Abstract: The invention in suitable embodiments is directed to an isolated protein comprising one or more amino acid sequences, each amino acid sequence capable of being functionalized and/or attached in whole and/or in part to one or more or a plurality of elements of one or more types including to cargo elements, forming a composition of elements suitable for use as an in vivo and/or in vitro medicament to treat one or more biological species.Type: ApplicationFiled: December 21, 2012Publication date: June 20, 2013Inventors: FRANCO VITALIANO, GORDANA DRAGAN VITALIANO
-
Publication number: 20130160159Abstract: A replication inhibitor, which is an agent for inhibiting replication of a geminivirus, and comprises a zinc finger protein that can specifically bind to at least full length of stem loop region DNA of the geminivirus, or a part thereof, and can inhibit formation of a stem loop structure.Type: ApplicationFiled: June 6, 2011Publication date: June 20, 2013Inventor: Takashi Sera
-
Publication number: 20130149321Abstract: The present invention relates to the use of plasminogen/plasmin and its derivatives as agents for enhancing host defense against infection or other infectious diseases. The invention also relates to a method for screening of compounds which enhance host defense against infection by evaluating the host defense against bacterial arthritis and spontaneous otitis media in an animal model.Type: ApplicationFiled: November 26, 2012Publication date: June 13, 2013Applicant: OMNIO HEALER ABInventor: OMNIO HEALER AB
-
Publication number: 20130150286Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.Type: ApplicationFiled: June 25, 2010Publication date: June 13, 2013Inventors: Jean-Claude Sirard, Jose A. Chabalgoity
-
Publication number: 20130150287Abstract: The present invention relates to a recombinant protein for siRNA delivery, which allows the efficient intracellular and in vivo delivery of siRNA. More particularly, the present invention relates to a recombinant protein that allows a siRNA binding protein to be located in the interior cavity of a capsid protein of HBV (Hepatitis B virus), in which siRNAs of interest bind to the siRNA binding protein to be encapsulated within the capsid shell, thereby providing stability against the external attack such as nucleases and achieving the efficient intracellular and in vivo delivery of siRNA by its release into the cytosolic space after cell uptake.Type: ApplicationFiled: December 7, 2011Publication date: June 13, 2013Applicant: Korea Institute of Science and TechnologyInventors: Hyung-Jun AHN, Ick-Chan Kwon, Kui-Won Choi
-
Publication number: 20130150290Abstract: The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides.Type: ApplicationFiled: February 1, 2013Publication date: June 13, 2013Applicant: Onyx Therapeutics, Inc.Inventor: Onyx Therapeutics, Inc.
-
Publication number: 20130150288Abstract: The present invention concerns polypeptides derived from a tandem repeat of apoE141-149 and their uses as medicaments. The peptides may comprise the tandem repeat, and truncations thereof, for which at least one Leucine (L) is replaced by an amino acid with a side chain comprising at least 4 carbon atoms and at least one Nitrogen atom. Such peptides are useful for preventing or treating viral infections.Type: ApplicationFiled: July 16, 2012Publication date: June 13, 2013Applicant: AI2 LIMITEDInventor: Curtis Dobson
-
Publication number: 20130150289Abstract: The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides.Type: ApplicationFiled: February 1, 2013Publication date: June 13, 2013Applicant: Onyx Therapeutics, Inc.Inventor: Onyx Therapeutics, Inc.
-
Patent number: 8461107Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.Type: GrantFiled: April 16, 2009Date of Patent: June 11, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Nigel J. Liverton, John A. McCauley, John W. Butcher, Kevin F. Gilbert, Charles J. McIntyre, Michael T. Rudd
-
Publication number: 20130143794Abstract: The present invention provides polypeptides according to the general formulas disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolated nucleic acids encoding the polypeptides of the invention, recombinant expression vectors comprising the nucleic acids encoding the polypeptides of the invention operatively linked to a suitable control sequence, and recombinant host cells comprising the recombinant expression vectors of the invention. The present invention also provides antibodies that selectively bind to the polypeptides of the invention, and pharmaceutical compositions comprising one or more polypeptides according to the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: August 3, 2011Publication date: June 6, 2013Applicant: University of Washington through its Center for CommercializationInventors: David Baker, Timothy A. Whitehead, Sarel Fleishman
-
Publication number: 20130130970Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antiviral activity, particularly against integrin-using viruses, more particularly against rotavirus. Further, the present invention refers to compositions comprising said peptidic compounds for medical use or for use as food additives.Type: ApplicationFiled: May 31, 2011Publication date: May 23, 2013Applicant: ROTALACTIS SRLInventors: Amedeo Conti, David Lembo, Claudio Fabris, Enrico Bertino, Santo Landolfo
-
Publication number: 20130129621Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.Type: ApplicationFiled: May 9, 2012Publication date: May 23, 2013Applicant: ALLEGRO PHARMACEUTICALS, INC.Inventors: Michael John Mackel, John Y. Park, Hampar L. Karageozian, Vicken H. Karageozian
-
Patent number: 8445430Abstract: The invention provides cyclic carboxamide compounds and analogues thereof of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain cyclic carboxamide compounds and cyclic carboxamide analogues disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more cyclic carboxamide compounds or cyclic carboxamide analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a cyclic carboxamide compound or cyclic carboxamide analogue as the only active agent or may contain a combination of a cyclic carboxamide compound or cyclic carboxamide analogue and one or more other pharmaceutically active agents.Type: GrantFiled: November 20, 2009Date of Patent: May 21, 2013Assignee: Achillion Pharmaceuticals, Inc.Inventors: Suoming Zhang, Avinash Phadke, Milind Deshpande, Venkat Gadhachanda
-
Publication number: 20130122046Abstract: Use of an ubiquitination pathway-related factor, its agonist or antagonist in the preparation of a composition for regulating FOXP3, IL-2, and/or IFN-? activity, in which the ubiquitination pathway-related factor is selected from: Toll-like receptor, ubiquitin ligase, pro-inflammatory cytokine family receptor, and/or its coding sequence. The new type of regulatory factors can regulate regulatory T cells and immune system by regulating FOXP3, IL-2, and/or IFN-? activity. The regulatory factors and their derivatives can also be used as immunoadjuvant for treating or preventing major diseases (such as, infectious diseases and tumor, etc).Type: ApplicationFiled: July 11, 2011Publication date: May 16, 2013Applicant: INSTITUT PASTEUR OF SHANGHAI, CASInventors: Bin Li, Fang Lin, Zuojia Chen, Zhiyuan Li, Fan Pan
-
Patent number: 8435939Abstract: The present invention provides novel polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like), and methods of using same in the treatment of HIV.Type: GrantFiled: August 25, 2009Date of Patent: May 7, 2013Assignee: Biokine Therapeutics Ltd.Inventor: Nobutaka Fujii
-
Publication number: 20130109618Abstract: The present invention provides a RNA virus-derived peptides with modified side chains, wherein the side chains of the RNA virus-derived peptide are modified by altering the side-chain length or charges thereof such that the RNA virus-derived peptide has a high binding affinity for viral RNA and an high cellular uptake capability. The present invention also provides a composition for inhibiting RNA virus wherein the RNA virus-derived peptide can effectively inhibit viral self-replication and treat related diseases by its high affinity for viral RNA. A drug delivery carrier is also provided, wherein the RNA virus-derived peptides can carry desired drugs to the intracellular target due to its cellular uptake capability and thereby enhances the drug-delivery and treating efficiency.Type: ApplicationFiled: April 5, 2012Publication date: May 2, 2013Applicant: National Taiwan UniversityInventors: Richard Ping Cheng, Cheng-Hsun Wu, Ming-Huei Weng, Li-Min Huang
-
Publication number: 20130109614Abstract: Enclosed is an antagonist, which includes a peptide chain represented by an amino acid sequence. The amino acid sequence has a short sequence, C-X1X2X3X4X5-N, which is situated before and neighbored to the third cysteine (Cys, C) of the N-terminus, wherein X1 is an amino acid with aromatic ring, hydrophobic property or long chain, and X2, X3, X4 and X5 are glutamine (G), serine (S), alanine (A) and proline (P) respectively. In one embodiment, X1 is phenylalanine (F). The present antagonists can be used to inhibit or treat with the diseases caused by the activated cells expressing CXCR1 and/or CXCR2 receptor, for example, the acute or chronic inflammatory reaction induced with polymorphonuclear neutrophils (PMNs) expressing CXCR1 and/or CXCR2 receptor, and angiogenesis accompanied by tumor growth inhibition.Type: ApplicationFiled: June 12, 2012Publication date: May 2, 2013Inventors: Jya-Wei Cheng, Kuo-Chun Huang, Hsi-Tsung Cheng, Hui-Yuan Yu
-
Publication number: 20130108653Abstract: The present invention relates to a new class of virus fusion inhibitors or virus entry inhibitors. More specifically the present invention relates to bivalent molecules that are pre-fusion inhibitors of viruses that makes use of the type (1) fusion mechanism belonging to the groups consisting of Othomyxoviridae, Paramyxoviridae, Retroviridae, Filoviridae and Coronaviridae, in particular HIV. The bivalent molecules of the present invention are molecules that comprise a first part capable of mimicking the function of a mammalian cell receptor, and a second part capable of binding to a virus, preferably HIV, resulting in the neutralization of the virus which is thus rendered harmless. Further, the present invention relates to compositions comprising the pre-fusion inhibitors, as well as to methods for obtaining the pre-fusion inhibitors and the use of the pre-fusion inhibitors.Type: ApplicationFiled: December 22, 2010Publication date: May 2, 2013Inventors: Shervin Bahrami, Martin Tolstrup, Mogens Duch Ryttergmrd, Finn Skou Pedersen, Lars Jørgen Ostergaard
-
Publication number: 20130109619Abstract: A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.Type: ApplicationFiled: May 11, 2011Publication date: May 2, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nadya I. Tarasova, Giorgio Trinchieri, Howard A. Young, C. Andrew Stewart, Marco A. Cardone, Alan O. Perantoni
-
Patent number: 8431530Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: GrantFiled: May 20, 2010Date of Patent: April 30, 2013Assignee: Morehouse School of MedicineInventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
-
Patent number: 8426360Abstract: The present invention discloses compounds of formula I, II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. More specifically, the invention relates to oxime compounds containing a carbocyclic P2 unit. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: November 13, 2008Date of Patent: April 23, 2013Assignee: Enanta Pharmaceuticals, Inc.Inventors: Dong Liu, Yat Sun Or, Zhe Wang
-
Patent number: 8426359Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.Type: GrantFiled: November 5, 2008Date of Patent: April 23, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Kevin M. Cottrell, Robert B. Perni, Janos Pitlik, Wayne C. Schairer
-
Publication number: 20130096051Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and re-search use. In particular, the present invention provides antiviral and antimicrobial lectin compounds (BanLec) isolated from bananas. These compounds have low mitogenicity and pro-inflammatory activity whilst maintaining anti-HIV-1 activity.Type: ApplicationFiled: April 11, 2011Publication date: April 18, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: David Markovitz, Michael Swanson, Irwin Goldstein, Harry Winter
-
Patent number: 8420596Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.Type: GrantFiled: September 10, 2009Date of Patent: April 16, 2013Assignees: Abbott Laboratories, Enanta Pharmaceuticals, Inc.Inventors: Yiyin Ku, Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, Dale J. Kempf, David J. Grampovnik
-
Patent number: 8420597Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: August 29, 2012Date of Patent: April 16, 2013Assignee: Gilead Sciences, Inc.Inventors: Aesop Cho, Michael O'Neil Hanrahan Clarke, Choung U. Kim, John O. Link, Hyung-jung Pyun, Xiaoning C. Sheng, Qiaoyin Wu
-
Publication number: 20130085097Abstract: Methods and compositions for preventing viral infection are disclosed. Compositions containing papillomavirus VLPs or capsomeres are used, alone or in combination with other agents, as microbicides that substantially block papillomavirus binding receptors on the surface or vicinity of cells in a tissue to be treated with the composition. The invention can be used to inhibit papillomavirus infection or infection by another virus that utilizes the same binding receptors during the infection process.Type: ApplicationFiled: March 22, 2011Publication date: April 4, 2013Applicant: UNIVERSITY OF ROCHESTERInventor: William Bonnez
-
Publication number: 20130071412Abstract: The invention features a powdered composition including a pharmaceutically active compound and a protein or a hydrolyzed protein. In particular, the powdered composition forms a stable solution or dispersion suitable for oral administration in which the protein or the hydrolyzed protein is bound to the pharmaceutically active compound. The invention also provides a method of administering the composition, such as to a patient with dysphasia; liquid or semi-solid formulations of the composition; methods for preparing the composition; and kits including the composition.Type: ApplicationFiled: December 17, 2010Publication date: March 21, 2013Applicant: Exodos Life Sciences Limited PartnershipInventors: Harry J. Leighton, Crist J. Frangakis
-
Publication number: 20130072424Abstract: Compounds comprising condensed particles having diameters less than 1000 nm, wherein the particles comprise one or more double stranded ribonucleic acids (dsRNAs) and one or more peptides. The compounds, compositions and methods are useful for modulating gene expression by RNA interference.Type: ApplicationFiled: May 18, 2012Publication date: March 21, 2013Applicant: MARINA BIOTECH, INC.Inventors: Roger C. Adami, Tianying Zhu, Kunyuan Cui, Michael E. Houston, JR., Lishan Chen, Yuching Chen
-
Publication number: 20130064809Abstract: A composition for prophylactic and/or therapeutic medicinal applications, or plant protection applications, in particular for the control of microorganisms, either planktonic or organized in biofilms. The composition includes at least one ion selected from hypohalite, at least one compound selected from lactoferrin, lactoferrin peptide, lysozyme, immunoglobulins or a combination thereof, optionally hypothiocyanite, and optionally at least one growth factor.Type: ApplicationFiled: August 6, 2012Publication date: March 14, 2013Inventor: Jean-Paul PERRAUDIN
-
Patent number: 8394764Abstract: An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viralType: GrantFiled: February 7, 2011Date of Patent: March 12, 2013Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Michael R. Boyd, Toshiyuki Mori, Barry R. O'Keefe
-
Publication number: 20130053306Abstract: There is provided a biologically-active agent, in particular, for the early diagnosis and/or preventative therapy of virally-infected living cells, the efficacy of which is selective for the cell membranes of the virally-infected cells, which are modified after viral infection. The agent includes at least one component, selected from a group of materials, including recombinant human histone H1 or at least an H1 subtype or the active portion thereof. The appropriate biological activity for killing a virally-infected cell at the modified cell membrane thereof through cooperation with similarly or differently active agent components may be achieved, which together form a biologically-effective complex with increased biological activity.Type: ApplicationFiled: March 30, 2012Publication date: February 28, 2013Inventor: Reiner Class
-
Publication number: 20130053303Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.Type: ApplicationFiled: October 5, 2012Publication date: February 28, 2013Applicant: Onyx Therapeutics, Inc.Inventor: Onyx Therapeutics, Inc.